MX2016001457A - Medicamentos terapeuticos de matriz extracelular endotelial corneal. - Google Patents
Medicamentos terapeuticos de matriz extracelular endotelial corneal.Info
- Publication number
- MX2016001457A MX2016001457A MX2016001457A MX2016001457A MX2016001457A MX 2016001457 A MX2016001457 A MX 2016001457A MX 2016001457 A MX2016001457 A MX 2016001457A MX 2016001457 A MX2016001457 A MX 2016001457A MX 2016001457 A MX2016001457 A MX 2016001457A
- Authority
- MX
- Mexico
- Prior art keywords
- disorders
- corneal
- ecm
- corneal endothelium
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Abstract
La presente invención proporciona medicamentos para tratar o prevenir un padecimiento, trastorno, o condición que se asocia con la anormalidad de la matriz extracelular (ECM) en un endotelio corneal, en donde los medicamentos comprenden un agente de inhibición de la señal del TGF-beta; más específicamente, este padecimiento, trastorno, o condición es un trastorno asociado con la distrofia corneal endotelial de Fuchs; tal trastorno incluye fotofobia, visión borrosa, trastorno de visión, dolor de ojos, lagrimeo, hiperemia, dolor, queratopatía bullosa, molestia oftálmica, una disminución en el contraste, deslumbramiento, edema en el estroma corneal, queratopatía bullosa, opacidad corneal, y similares; un agente de inhibición de la señal del TGF-beta preferible incluye 4-[4-(1,3-benzodioxol-5-il)-5-(2-pirid inil)-1H-imidazol-2-il]benzamida.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2013/071095 WO2015015654A1 (ja) | 2013-07-30 | 2013-07-30 | 角膜内皮ecm治療薬 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016001457A true MX2016001457A (es) | 2016-11-11 |
Family
ID=52431224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016001457A MX2016001457A (es) | 2013-07-30 | 2013-07-30 | Medicamentos terapeuticos de matriz extracelular endotelial corneal. |
Country Status (7)
Country | Link |
---|---|
US (2) | US11730722B2 (es) |
JP (1) | JP6403217B2 (es) |
BR (1) | BR112016002015A2 (es) |
CA (1) | CA2919316C (es) |
MX (1) | MX2016001457A (es) |
RU (1) | RU2016106641A (es) |
WO (1) | WO2015015654A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11730722B2 (en) | 2013-07-30 | 2023-08-22 | Kyoto Prefectural Public University Corporation | Corneal endothelium ECM therapeutic medicaments |
EP3064222B1 (en) * | 2013-10-31 | 2020-10-21 | Kyoto Prefectural Public University Corporation | Therapeutic drug comprising tgf-beta signal inhibitor for diseases related to endoplasmic reticulum cell death in corneal endothelium |
EP3639854A4 (en) | 2017-06-16 | 2021-03-03 | The Doshisha | MTOR INHIBITIVE MEDICINAL PRODUCT FOR THE TREATMENT OR PREVENTION OF OPHTHALMIC SYMPTOMS, DISORDERS, OR DISEASES AND USE THEREOF |
US20200386744A1 (en) * | 2017-06-16 | 2020-12-10 | The Doshisha | Novel screening method for tgf-beta inhibitor |
JP7398729B2 (ja) * | 2017-12-13 | 2023-12-15 | 学校法人同志社 | (t)ew-7197を含む角膜内皮疾患を治療または予防するための組成物または方法 |
JPWO2020009248A1 (ja) * | 2018-07-04 | 2021-08-12 | 京都府公立大学法人 | 眼組織の線維化抑制用組成物 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5703047A (en) * | 1992-09-21 | 1997-12-30 | Board Of Regents, The University Of Texas System | Methods and treatments for corneal healing with growth factors |
WO1998024466A1 (en) * | 1996-12-05 | 1998-06-11 | Alcon Laboratories, Inc. | THE USE OF INHIBITORS OF TGF-β'S FUNCTIONS TO AMELIORATE OCULAR PATHOLOGY |
ES2146552B1 (es) | 1998-11-24 | 2001-04-16 | Inst Cientifico Tecnol Navarra | Peptidos inhibidores de tgf/31 |
ES2198367T3 (es) | 1999-10-29 | 2004-02-01 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh | Uso de gdnf para tratar defectos de la cornea. |
JP2003530353A (ja) * | 2000-04-07 | 2003-10-14 | キム,サン,ギョン | オルチプラズの肝繊維化及び肝硬変症進行の予防及び治療剤としての使用方法、及びオルチプラズを主成分として含有する製薬組成物 |
AU2003229305A1 (en) | 2002-05-17 | 2003-12-02 | Scios, Inc. | TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-Beta INHIBITORS |
JPWO2004018430A1 (ja) | 2002-08-23 | 2005-12-08 | 麒麟麦酒株式会社 | TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物 |
US8158589B2 (en) * | 2003-08-22 | 2012-04-17 | Proyecto Biomedicine Cima, S.L. | Peptides with the capacity to bind to transforming growth factor β1 (TGF-β1) |
AU2005284798B2 (en) | 2004-09-15 | 2012-02-02 | The President And Fellows Of Harvard College | Reducing ER stress in the treatment of obesity and diabetes |
JP2008530100A (ja) | 2005-02-10 | 2008-08-07 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 視覚障害の治療方法 |
KR100657935B1 (ko) * | 2005-03-08 | 2006-12-14 | 메디제네스(주) | TGF-β에 대한 항체를 포함하는 아벨리노각막이영양증의 치료용 약학 조성물 |
KR20080082618A (ko) | 2005-12-16 | 2008-09-11 | 알콘, 인코퍼레이티드 | Alk5 조절제를 사용한 안압의 조절 |
EP2192904B1 (en) | 2007-08-27 | 2016-08-17 | Auxagen, Inc. | METHODS FOR INHIBITING TGF-beta |
JP2011521969A (ja) | 2008-05-30 | 2011-07-28 | スムマ ヘルス システムズ エルエルシー | 眼疾患を治療するためのTGF−β受容体阻害剤又はアクチビン様キナーゼ(ALK)5阻害剤、A−83−01及びSB−431542の使用方法及び創傷治療条件 |
WO2010121162A1 (en) * | 2009-04-17 | 2010-10-21 | Summa Health Systems Llc | Use of transforming growth factor-b receptor inhibitors to suppress ocular scarring |
WO2012009171A2 (en) * | 2010-07-15 | 2012-01-19 | The Schepens Eye Research Institute, Inc. | Compositions and methods of treatment of corneal endothelium disorders |
KR101258166B1 (ko) | 2010-09-01 | 2013-04-25 | 연세대학교 산학협력단 | Tgfbi 유전자 변이 각막 이상증의 예방 또는 치료용 약제학적 조성물 및 그의 스크리닝 방법 |
US9574171B2 (en) | 2010-12-02 | 2017-02-21 | Technion Research & Development Foundation Ltd. | Methods of generating corneal cells and cell populations comprising same |
RS58526B1 (sr) | 2011-12-06 | 2019-04-30 | Astellas Inst For Regenerative Medicine | Postupak usmerene diferencijacije koja proizvodi kornealne endotelijalne ćelije |
EP2799537B1 (en) | 2011-12-28 | 2021-09-22 | Kyoto Prefectural Public University Corporation | Normalization of culture of corneal endothelial cells |
US11730722B2 (en) | 2013-07-30 | 2023-08-22 | Kyoto Prefectural Public University Corporation | Corneal endothelium ECM therapeutic medicaments |
EP3064222B1 (en) | 2013-10-31 | 2020-10-21 | Kyoto Prefectural Public University Corporation | Therapeutic drug comprising tgf-beta signal inhibitor for diseases related to endoplasmic reticulum cell death in corneal endothelium |
-
2013
- 2013-07-30 US US14/907,881 patent/US11730722B2/en active Active
- 2013-07-30 JP JP2015529317A patent/JP6403217B2/ja active Active
- 2013-07-30 RU RU2016106641A patent/RU2016106641A/ru unknown
- 2013-07-30 WO PCT/JP2013/071095 patent/WO2015015654A1/ja active Application Filing
- 2013-07-30 MX MX2016001457A patent/MX2016001457A/es unknown
- 2013-07-30 CA CA2919316A patent/CA2919316C/en active Active
- 2013-07-30 BR BR112016002015A patent/BR112016002015A2/pt not_active Application Discontinuation
-
2023
- 2023-06-07 US US18/330,510 patent/US20230310402A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JPWO2015015654A1 (ja) | 2017-03-02 |
RU2016106641A (ru) | 2017-09-01 |
JP6403217B2 (ja) | 2018-10-10 |
US20160158210A1 (en) | 2016-06-09 |
CA2919316A1 (en) | 2015-02-05 |
CA2919316C (en) | 2021-08-10 |
WO2015015654A1 (ja) | 2015-02-05 |
US20230310402A1 (en) | 2023-10-05 |
BR112016002015A2 (pt) | 2017-08-01 |
US11730722B2 (en) | 2023-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016001457A (es) | Medicamentos terapeuticos de matriz extracelular endotelial corneal. | |
NZ588938A (en) | Sustained release delivery of active agents to treat glaucoma and ocular hypertension | |
MX2010003774A (es) | Formulaciones oftalmicas acuosas. | |
FI3811943T3 (fi) | Yhdiste käytettäväksi silmäsairauksien hoidossa | |
NZ610230A (en) | Compositions and methods for treating ocular edema, neovascularization and related diseases | |
MY170198A (en) | Agent for treatment of dry eye characterized by combining p2y2 receptor agonist and hyaluronic acid or salt thereof, method for treating dry eye, and use of the p2y2 receptor agonist and hyaluronic acid or salt thereof | |
MX2016014634A (es) | Compuestos para el tratamiento de enfermedades y trastornos oftalmicos. | |
BR112014008789A2 (pt) | prevenção e tratamento de condições oculares | |
NZ601547A (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
PH12015501938B1 (en) | Ocular formulations for drug-delivery to the posterior segment of the eye | |
EP4302734A3 (en) | Ocular delivery systems and methods | |
JP2011516477A5 (es) | ||
MX2016005680A (es) | Farmaco terapeutico para enfermedades relacionadas con la muerte celular del reticulo endoplasmico en el endotelio de cornea. | |
PH12019500423A1 (en) | Pharmaceutical composition | |
MY150250A (en) | Ketorolac tromethamine compositions for treating or preventing ocular pain | |
TNSN08338A1 (en) | The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron | |
WO2011151685A8 (en) | N-acetyl-dl-leucine, neuroprotective and retinoprotective medicament | |
JP2013534527A5 (es) | ||
MX355770B (es) | Composicion farmaceutica de ibuprofeno y tramadol para uso oftalmico. | |
MX2016016090A (es) | Composicion oftalmica para el tratamiento de infeccion ocular. | |
AR092842A1 (es) | Tratamiento de enfermedades inflamatorias oculares usando laquinimod | |
RU2017118405A (ru) | Новое лечение роговицы с применением ламинина | |
RU2017111579A (ru) | Способы лечения и предотвращения заболеваний глаз, расстройств и патологических состояний меланином и аналогами, предшественниками и производными меланина | |
PH12020550722A1 (en) | Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye | |
TN2016000259A1 (en) | Salbutamol (albuterol) eye protective medicament. |